Media

All the posts published.

PDS Phase 2 Clinical Trial Update

Oct 21, 2021
-
Media, News, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Phase 2 Clinical Trial Update PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination   London, UK – 21 October 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group,  announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced the temporary…

PDS Phase 2 Clinical Trial Update

Oct 5, 2021
-
Media, News, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Phase 2 Clinical Trial Update   PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer     London, UK – 05 October 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group,  announces that…

Investor Presentations

Oct 4, 2021
-
Media, News, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") Investor Presentations   London, UK – 04 October 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, today outlines its investor communications timetable for the remainder of the year.   Management will be presenting at a range of virtual retail focussed investor events, to discuss the Company’s recent results…

Grant of Options to Directors

Sep 29, 2021
-
Media, News, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") Grant of Options to Directors London, UK – 29 September 2021 – NetScientific plc (AIM:NSCI), the international life sciences and sustainability, technology investment and commercialisation group, announces that on  28 September 2021 it granted a further 183,191 options over ordinary shares of 5p each (the "Ordinary Shares") to each of its Chief Executive Officer, Dr Ilian Iliev, and its Executive…

Interim Results for the six months ended 30 June 2021

Sep 29, 2021
-
Media, News, RNS Announcements
NetScientific plc (“NetScientific” or the “Company” or the “Group”) Interim Results for the six months ended 30 June 2021   London, UK - 29 September 2021: NetScientific Plc (AIM: NSCI), the international life sciences and sustainability, technology investment and commercialisation group, today announces its interim results for the six months ended 30 June 2021.   2021 reinforced the excellent progress made to date, which…

Notice of Results and Analyst Briefing

Sep 20, 2021
-
Media, News, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") Notice of Results and Analyst Briefing   London, UK – 29 September 2021 – NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, is expected to announce results for the half year ended 30 June 2021 on Wednesday 29 September 2021. Analyst Briefing: 09.30, Wednesday 29 September Management will be hosting…

Investment in Martlet Capital Limited

Sep 16, 2021
-
Media, News, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") Investment in Martlet Capital Limited    London, UK – 16 September 2021 – NetScientific plc (AIM: NSCI), an active holding company in life sciences and sustainability technology investment, is pleased to announce an initial £1m investment in Martlet Capital Limited (“Martlet Capital”), which intends to acquire a portfolio of minority interests in the Cambridge high-tech cluster. NetScientific’s…

NetScientific gaining critical mass with commercial ramp-up of portfolio

Dec 14, 2017
-
Media, News
Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) caught up with Proactive’s Andrew Scott to update on developments within the IP commercialisation specialist’s portfolio. https://youtu.be/_5_-vQTbvp0 Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), caught up with Proactive's Andrew Scott to update on developments within the IP commercialisation specialist's portfolio. ''All of our companies are game-changing and unique in their sectors'', Martelet says. Most recently…

NetScientific H1 2018 Planned Investor Event and Conference Attendance

Jan 6, 2018
-
Media, News
London, UK – 05 January 2018 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces that its management team will attend the following key investor and partnering conferences in the first half of 2018: IDATE DigiWorld – London Members Yearly Meeting January 18th 2018 London, UK Francois Martelet, CEO, to attend   BAB TAG Networking Event January 24th 2018 London, UK…

NetScientific CEO to Present at Shares Investor Evening at 19:30 on the 14th December 2017

Dec 8, 2017
-
Media, News
  London, UK – 08 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group announces that Francois Martelet, Chief Executive Officer, will be presenting at the Shares Investor Evening in London at the Novotel Tower Bridge, London EC3N 2NR on Thursday 14 December at 19:30 GMT # # # For more information, please contact: NetScientific François R. Martelet, M.D., CEO…
Media Archives - NetScientific